Preclinical News and Research

RSS
Vaccine for human cytomegalovirus

Vaccine for human cytomegalovirus

Toronto at forefront of stem cell technology

Toronto at forefront of stem cell technology

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

Anacor finds novel mechanism for lead anti-fungal drug, AN2690

PepTcell vaccine could provide immunity against all strains of influenza virus

PepTcell vaccine could provide immunity against all strains of influenza virus

Reports of abnormal behaviour sends Tamiflu back to the drawing board

Reports of abnormal behaviour sends Tamiflu back to the drawing board

Newer breast cancer drug may protect heart

Newer breast cancer drug may protect heart

What causes Alzheimer's disease?

What causes Alzheimer's disease?

World's first PET/MR images of the human brain

World's first PET/MR images of the human brain

Nanoparticle delivery of insulin gene to fight juvenile diabetes developed

Nanoparticle delivery of insulin gene to fight juvenile diabetes developed

Novel preclinical gene therapy approach for treating Niemann-Pick disease

Novel preclinical gene therapy approach for treating Niemann-Pick disease

Targeted nanoparticles offer promising techniques for cancer treatment

Targeted nanoparticles offer promising techniques for cancer treatment

Nanomedicine opens the way for nerve cell regeneration

Nanomedicine opens the way for nerve cell regeneration

Oncolytic viruses deliver a knockout punch to cancers

Oncolytic viruses deliver a knockout punch to cancers

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

Bristol-Myers Squibb collaborates with Isis Pharmaceuticals

New vaccine breakthrough for respiratory syncytial virus

New vaccine breakthrough for respiratory syncytial virus

Promising new target for brain tumor therapy

Promising new target for brain tumor therapy

LigoCyte Pharmaceuticals presents data showing that immunization with their influenza H1N1-VLP formulation resulted in 100% protection from H1N1 and H3N2

LigoCyte Pharmaceuticals presents data showing that immunization with their influenza H1N1-VLP formulation resulted in 100% protection from H1N1 and H3N2

Mesoblast receives FDA clearance for heart attack stem cell trial

Mesoblast receives FDA clearance for heart attack stem cell trial

Revolutionary treatment for blindness

Revolutionary treatment for blindness

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.